What are the recommended COVID-19 treatments for patients aged 65 years or older with established cardiovascular disease presenting with mild-to-moderate infection?

Recommended COVID-19 Treatments for Elderly Patients with Heart Disease

For elderly patients (≥65 years) with established cardiovascular disease and mild-to-moderate COVID-19, nirmatrelvir/ritonavir (Paxlovid) is the first-line antiviral treatment, with critical attention to drug-drug interactions requiring temporary substitution of certain anticoagulants with low-molecular-weight heparin during the 5-day treatment course. 1

Antiviral Therapy Selection

First-Line: Nirmatrelvir/Ritonavir (Paxlovid)

• Nirmatrelvir/ritonavir is the preferred oral antiviral for high-risk elderly patients with heart disease when no contraindications exist, offering superior efficacy compared to other oral antivirals and reducing long-term major adverse cardiovascular events (MACE) by approximately 35% 1, 2

• Critical drug interaction management is mandatory: Ritonavir markedly increases plasma concentrations of rivaroxaban, apixaban, and other CYP3A4-metabolized drugs 1

• For patients on rivaroxaban or apixaban, switch to therapeutic-dose LMWH during the 5-day Paxlovid course to avoid dramatically elevated bleeding risk 1

• Warfarin may be continued with Paxlovid but requires more frequent INR monitoring (every 2-3 days during treatment) 1

• Nirmatrelvir/ritonavir reduces long-term cardiovascular events most effectively in patients aged ≥40 years, with hazard ratios of 0.60 for ages 41-64 and 0.68 for ages ≥65 2

Second-Line: Remdesivir

• Remdesivir is recommended for hospitalized patients or high-risk outpatients when Paxlovid-related drug interactions are prohibitive 1, 3

• Remdesivir has no significant interactions with anticoagulants or antiplatelet agents, making it ideal for patients on complex cardiovascular regimens 1

• Renal function must be monitored throughout remdesivir therapy, especially in elderly patients with baseline renal impairment 1

• Remdesivir may result in larger reductions in hospital admission compared to molnupiravir (low certainty evidence) 4

Third-Line: Molnupiravir

• Molnupiravir is conditionally recommended only for patients with non-severe COVID-19 at high risk of hospitalization when nirmatrelvir/ritonavir and remdesivir are not feasible 4, 1

• Molnupiravir lacks CYP3A4 interactions but is less effective than Paxlovid, with moderate certainty evidence of reduced hospitalizations and mortality 4

• Molnupiravir reduces long-term MACE with a hazard ratio of 0.75, though less effectively than nirmatrelvir/ritonavir 2

• Safety concerns include potential long-term carcinogenesis risk based on preclinical mutagenic data (very low certainty), though no human long-term follow-up data exist 4

Cardiovascular Medication Management

Anticoagulation

• Therapeutic anticoagulation (warfarin, DOACs, or LMWH) must be continued unchanged at the pre-infection dose for patients on these agents for atrial fibrillation, prior stroke, or other indications 1, 4

• Never discontinue chronic anticoagulation solely because of COVID-19 diagnosis 1, 4

• In non-ICU hospitalized patients already receiving therapeutic anticoagulation, maintain the regimen; prophylactic-dose LMWH is added only if the patient is not already therapeutically anticoagulated 1

• Do not add prophylactic-dose anticoagulation on top of an existing therapeutic regimen, as this raises bleeding risk without proven benefit 1

• In ICU settings, consider switching from oral anticoagulants to LMWH or unfractionated heparin to allow easier titration and rapid reversal if needed 1

• Baseline and serial monitoring of platelet count, PT/INR, aPTT, liver enzymes, and renal function is required before and during COVID-19 treatment 1

Antiplatelet Therapy

• Dual antiplatelet therapy (DAPT) must be continued unchanged in patients with recent ACS (≤1 year) or recent PCI/stent placement 1, 4

• Single antiplatelet therapy is maintained in patients with prior stroke or stable coronary artery disease 1, 4

• Do not discontinue antiplatelet therapy solely because of COVID-19 infection 1, 4

• New antiplatelet agents should not be started in patients with myocardial injury unless a definitive ACS is diagnosed 1, 4

• When prophylactic-dose anticoagulation is prescribed for COVID-19, patients already on DAPT should continue both agents 1, 4

• For patients on DAPT receiving therapeutic-dose parenteral anticoagulation for COVID-19, individualize decisions considering bleeding risk (conditional recommendation) 4

Critical Drug Interaction Algorithm

Step 1: Identify current anticoagulation status

• If on warfarin: Continue warfarin + Paxlovid with INR monitoring every 2-3 days 1
• If on rivaroxaban or apixaban: Switch to therapeutic LMWH for 5 days during Paxlovid OR choose remdesivir instead 1
• If on dabigatran or edoxaban: May continue with caution; consider remdesivir if concerned 1

Step 2: Verify antiplatelet regimen

• Continue all antiplatelet therapy unchanged regardless of antiviral choice 1, 4

Step 3: Select antiviral

• First choice: Nirmatrelvir/ritonavir if drug interactions managed 1, 3
• Second choice: Remdesivir if interactions prohibitive 1, 3
• Third choice: Molnupiravir only if both above unavailable 4, 1

Cardiovascular Monitoring Requirements

• Obtain baseline and serial high-sensitivity troponin, BNP/NT-proBNP, and 12-lead ECG in elderly patients with pre-existing heart disease who develop COVID-19 1

• Continuous monitoring for arrhythmias—particularly new-onset atrial fibrillation and ventricular tachyarrhythmias—is advised 1

• Recognize that elevated troponin in COVID-19 does not automatically indicate plaque rupture; DAPT should not be started without confirmed ACS 1, 4

• Repeat coagulation studies and renal function tests during treatment, especially when remdesivir is administered or when patients are on anticoagulation 1

Special Cardiac Conditions

Recent ACS or PCI

• Continue DAPT unchanged regardless of hospitalization status 1, 4
• If receiving prophylactic anticoagulation for COVID-19, continue both antiplatelet agents 4

Atrial Fibrillation

• Continue the existing oral anticoagulant (DOAC or warfarin) without alteration 1, 4
• Do not add antiplatelet therapy unless another indication exists (e.g., recent ACS, prior stroke) 1, 4
• For new-onset AF during COVID-19, initiate anticoagulation based on CHA₂DS₂-VASc score as per standard guidelines 4

Peripheral Artery Disease

• Maintain antiplatelet therapy when patients are also receiving prophylactic-dose anticoagulation 1, 4
• If on single antiplatelet plus therapeutic anticoagulation, individualize continuation based on bleeding risk 1

Common Pitfalls to Avoid

• Never combine Paxlovid with rivaroxaban or apixaban without dose adjustment or temporary LMWH substitution, as this dramatically raises bleeding risk 1

• Do not start DAPT based solely on elevated troponin; myocardial injury in COVID-19 often reflects cytokine-mediated damage rather than plaque rupture 1, 4

• Avoid discontinuing chronic cardiovascular medications (ACE inhibitors, ARBs, statins, beta-blockers) during COVID-19, as these may provide protective effects 5, 6

• Do not overlook renal function monitoring when using remdesivir in elderly patients with baseline kidney disease 1